AI in Healthcare May 22, 2020
Dave Pearson

Researchers have demonstrated a way to visually explore small-molecule inhibitors that, according to algorithmic suggestions, show potential for targeting COVID-19’s main proteins.

The team, comprised of investigators at the San Diego virtual-reality startup Nanome and an AI drug-discovery company based in Hong Kong, Insilico Medicine, describe their work in ResearchGate and chemrxiv.org.

Nanome has additionally sent an announcement describing the collaboration’s technical advancement in lay language.

“Many potential therapeutics aimed at containing the spread of SARS-CoV-2 have targeted the S, or spike, protein, a surface protein that plays a vital role...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Healthcare System, Metaverse/VR, Pharma / Biotech, Public Health / COVID, Technology
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Walgreens Suffers $6 Billion Loss As VillageMD Clinic Investment Sours

Share This Article